iFR and FFR are equally safe to diagnose and treat heart disease according to largest-ever analysis of new real-world, long-term data
26 Ottobre 2023 - 10:00AM
iFR and FFR are equally safe to diagnose and treat heart disease
according to largest-ever analysis of new real-world, long-term
data
October 26, 2023
- Safety of Philips’ iFR in the guidance of percutaneous coronary
intervention (PCI) for heart disease demonstrated in late-breaking
science at TCT 2023 highlighting patient-level outcomes analysis of
42,000 patients from the National Swedeheart Quality Registry
- Previous data demonstrate that iFR delivers consistent patient
outcomes, reduces discomfort and offers a more cost-effective and
faster diagnostic solution [1,2] compared to FFR
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced the latest results demonstrating the safety of Philips
instant wave-free ratio (iFR) in the guidance of PCI.
Philips is committed to clinically validating its innovations in
cardiac and cardiovascular care. iFR is an innovative
pressure-derived index only offered by Philips that is used to
assess coronary blockages during interventional procedures. iFR
avoids the use of hyperemic agents, a class of drugs that maximize
blood flow but have a significant impact on the patient experience
[3].
A longitudinal analysis from the National Swedeheart Quality
Registry of more than 42,000 patients undergoing coronary
procedures, showed no difference between iFR and fractional flow
reserve (FFR) in major adverse cardiac events (MACE) [4]. The
analysis, “Long-term Safety of Revascularization Deferral Based on
Instantaneous Wave-Free Ratio or Fractional Reserve,” compares
patient outcomes using iFR and FFR in the diagnosis and treatment
of heart disease.
“These new findings once again confirm the safety of iFR. We
continue to see that iFR-guided treatment offers consistent
outcomes, reduces costs, and provides a better patient experience,”
said Dr. Götberg, Department of Cardiology, Clinical Sciences, Lund
University, Sweden, who presented the results during a
late-breaking science session at the Transcatheter Cardiovascular
Therapeutics (TCT) annual meeting in San Francisco. “The data from
this new analysis provides additional confidence in the safety of
iFR for physicians.”
In the previously published analysis of the five-year outcomes
of the randomized trial iFR-SWEDEHEART, results found iFR and FFR
to be equally safe and effective with respect to risks for MACE.
The cumulative MACE risks for each group differentiated by 1.6%
(iFR: 21.5%, FFR: 19.9%, HR 1.09 (95% CI: 0.90-1.33 at 5 years).
There was no difference in risk for death, heart attack or new
revascularization [3].
The results presented today from the SWEDEHEART registry
revealed that patients in the iFR group had more risk factors
compared with the FFR group but when adjusted for known confounders
there was no difference in 5-year MACE between patients who
underwent iFR or FFR-guided revascularization (32.2% vs. 31.3%,
adjusted HR 0.99, 95%CI 0.93–1.05, p=0.65). Furthermore, the
outcome was similar in the individual components of MACE (death,
heart attack, new revascularization) as well as in both deferred
and treated subgroups.
Patient discomfort can be reduced by 95.7
percentiFR is considered the Gold Standard for
hyperemia-free physiologic assessment for measuring pressure in
diagnostic and interventional procedures [1,4]. Similar to FFR,
clinicians use these tools coupled with angiographic images to
assess coronary blockages. However, by avoiding administrating a
hyperemic agent, patient discomfort can be reduced by 95.7 percent
and enables iFR to detect disease processes downstream from the
major blood vessels [4].
Only Philips iFR has a Class IA recommendation by the American
College of Cardiology, American Heart Association, Society for
Cardiovascular Angiography & Interventions and European Society
of Cardiology [1,2].
“We are confident in our pursuit of innovation to improve
outcomes and ensure patient safety. The data continues to
demonstrate the benefits of iFR-guided treatment to reduce costs
and improve outcomes,” said Chris Landon, General Manager, Philips
Image Guided Therapy Devices. “iFR technology is unique to Philips,
and we are proud to offer the global gold standard treatment for
patients with ischemic heart disease.”
For more information on Philips and the iFR data, please
visit http://www.philips.com/iFR and follow the #TCT2023
conversation with @PhilipsLiveFrom throughout the
event.
[1] Lawton J. et al. 2021 ACC/AHA/SCAI Guideline for Coronary
Artery Revascularization. JACC. 2022;79(2):e21-e129.[2] 2018
ESC/EACTS Guidelines on myocardial revascularization: The task
force on myocardial revascularization of the European society of
cardiology (ESC) and European association for cardio-thoracic
surgery (EACTS). Eur Heart J. 2018;00:1-96. Japan guidelines.[3]
Gotberg M, et al. Instantaneous wave-free ratio compared with
fractional flow reserve in PCI: A cost-minimization analysis. Int J
Cardiol 2021 1;344:54-59.[4] Gotberg M, Berntorp K, Rylance R, et
al. 5 – Year outcomes of PCI guided by measurement of instantaneous
wave-free ratio versus fractional flow reserve. J Am Coll Cardiol.
2022;79(10):965–974.
For further information, please contact:Joost
MalthaPhilips Global Press OfficeTel. : +31 6 10558116E-mail:
joost.maltha@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being through meaningful innovation. Philips’ patient- and
people-centric innovation leverages advanced technology and deep
clinical and consumer insights to deliver personal health solutions
for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, ultrasound, image-guided therapy, monitoring
and enterprise informatics, as well as in personal health. Philips
generated 2022 sales of EUR 17.8 billion and employs approximately
70,700 employees with sales and services in more than 100
countries. News about Philips can be found at
www.philips.com/newscenter.
- Philips iFR
- iFR co-registration
Grafico Azioni Koninklijke Philips NV (EU:PHIA)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Koninklijke Philips NV (EU:PHIA)
Storico
Da Apr 2023 a Apr 2024